ONCTERNAL THERAPEUTICS
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Their pipeline has recently expanded and now includes two clinical-stage products with common regulatory and development strategies. Oncternal Therapeutics cutting-edge scientific approach is focused on targets that are uniquely expressed within cancer cells, resulting in highly targeted new therapies. They also apply a variety of therapeutic strategies to address different medical challenges - from antibodies and antibody-drug conjugates (ADCs) to small molecules and chimeric antigen receptor T-cells (CAR-T).
ONCTERNAL THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Therapeutics
Founded:
2013-01-01
Address:
Encinitas, California, United States
Country:
United States
Website Url:
http://www.oncternal.com
Total Employee:
11+
Status:
Active
Contact:
(858)434-1113
Email Addresses:
[email protected]
Total Funding:
132.01 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Stemline Therapeutics
Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-03-07 | GTx | GTx acquired by Oncternal Therapeutics | N/A |
Key Employee Changes
Official Site Inspections
http://www.oncternal.com Semrush global rank: 6.69 M Semrush visits lastest month: 874
- Host name: 209.182.196.37
- IP address: 209.182.196.37
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Oncternal Therapeutics"
About Us - Oncternal Therapeutics
Who We Are Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments to treat hematological malignancies and prostate cancer across multiple …See details»
Leadership Team - Oncternal Therapeutics
Ms. Pietrofeso joined Oncternal in September 2021 as Senior Director Clinical Operations and was promoted to VP Clinical Development Operations in September 2022. Ms. ... is a former …See details»
Oncternal Therapeutics - Crunchbase Company Profile …
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class and novel therapies for both rare and common cancers. Their pipeline …See details»
Oncternal Therapeutics - LinkedIn
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need.See details»
Oncternal Therapeutics - Funding, Financials, Valuation & Investors
Oncternal Therapeutics is registered under the ticker NASDAQ:ONCT . Oncternal Therapeutics is funded by 2 investors. Global Source Ventures and Mesa Verde Venture Partners are the …See details»
Oncternal Therapeutics, Inc. Company Profile - Dun & Bradstreet
Doing Business As: Oncternal. Company Description: GTx knows hormones are just as important to men as they are to women. The company develops therapies targeting estrogens and …See details»
Oncternal Therapeutics, Inc. - AnnualReports.com
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet …See details»
Committee Composition - Oncternal Therapeutics, Inc.
The Investor Relations website contains information about Oncternal Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Oncternal Oncology, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Oncternal Oncology, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
The Science Behind Oncternal Therapeutics
Novel, Targeted Therapies With our scientific collaborators and advisors, we are leaders in the scientific areas underpinning our two clinical pipeline products: cirmtuzumab, an anti-ROR1 …See details»
Oncternal Therapeutics signs definitive merger agreement with GTx
Mar 8, 2019 The merged entity will operate as Oncternal Therapeutics. Oncternal Therapeutics co-founder, president and CEO James Breitmeyer said: “This merger introduces Oncternal …See details»
Vision, Mission and Impact - oncternal.net
Oncternal Therapeutics; Menu; About Overview Leadership Back Pipeline Overview ONCT-808 ONCT-534 Zilovertamab Back Science Overview Publications Back Investors Overview News …See details»
Oncternal stock sinks 60% amid layoffs, trial terminations
Sep 12, 2024 Oncternal folds all clinical trials after lackluster data drop, patient death By Gabrielle Masson Sep 12, 2024 10:51am Oncternal Therapeutics Cell & Gene Therapy layoffs …See details»
About Us - Oncternal Therapeutics
Who We Are Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments to treat hematological malignancies and prostate cancer across multiple …See details»
Oncternal shares to be delisted from Nasdaq - Investing.com
Nov 25, 2024 Oncternal has also terminated several clinical trials, including those for ONCT-534 and ONCT-808, treatments for metastatic castration-resistant cancer and aggressive B-cell …See details»
Oncternal Therapeutics, Inc. (Oncternal Therapeutics, Inc.) - 药物管 …
了解Oncternal Therapeutics, Inc. (Oncternal Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的33项临床试验, 115篇新闻和94篇文献，疾病领域:肿瘤，血液及淋巴系统疾 …See details»
Vision, Mission and Impact - Oncternal Therapeutics
Our VISIONUnwavering focus on oncology research and developlment to cure cancer Our MISSIONCreate a wave of innovation treatments to enrich the lives and health of patients with …See details»
Oncternal Therapeutics Announces Termination of its Clinical
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its decision to discontinue its clinical trials …See details»
Oncternal Therapeutics Announces Intent to Voluntarily Delist …
Oncternal undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or …See details»
Oncternal Therapeutics (ONCT) Earnings Date and Reports 2025
5 days ago Oncternal Therapeutics issued Q2 2024 earnings on August 8, 2024, reporting an EPS of -$2.89, which beat analysts' consensus estimates of -$3.03 by $0.14. Quarterly …See details»